Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease. The trial ...